公开(公告)号：WO2011154976A2

公开(公告)日：2011-12-15

申请号：PCT/IN2011/000379

申请日：2011-06-07

Applicant: PANACEA BIOTEC LIMITED ,  JAIN, Rajesh ,  VINAYAK, Virender Kumar ,  SINGH, Sukhjeet ,  AGARWAL, Neeraj ,  PATRA, Ashok ,  JAMBU, Lavit

Inventor： JAIN, Rajesh ,  VINAYAK, Virender Kumar ,  SINGH, Sukhjeet ,  AGARWAL, Neeraj ,  PATRA, Ashok ,  JAMBU, Lavit

IPC: A61K39/145

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/55566 ,  C12N7/02 ,  C12N2760/16134

Abstract: The present invention relates to novel process for purification of influenza viruses and the highly pure influenza virus obtained by such process. The invention is based on the premise that specific modification of viral purification processes can lead to increases in the yield, purity and robustness. The invention also provides an improved, low dose, stable, safe and efficacious compositions for easy administration to subjects and their use in augmenting immune responses to influenza antigens.

Abstract translation: 本发明涉及用于纯化流感病毒的新颖方法和通过该方法获得的高纯度流感病毒。 本发明基于病毒纯化过程的具体修饰可导致产量，纯度和鲁棒性提高的前提。 本发明还提供了一种改进的，低剂量，稳定，安全和有效的组合物，用于容易地施用于受试者及其用于增加对流感抗原的免疫应答。

公开(公告)号：WO2010038241A2

公开(公告)日：2010-04-08

申请号：PCT/IN2009/000540

申请日：2009-09-30

Applicant: PANACEA BIOTEC LIMITED ,  JAIN, Rajesh ,  SINGH, Sukhjeet

Inventor： JAIN, Rajesh ,  SINGH, Sukhjeet

IPC: A61K9/48 ,  A61K31/4439 ,  A61K47/36 ,  A61P1/04

CPC classification number: A61K31/4439 ,  A61K9/1652 ,  A61K9/284 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/286 ,  A61K9/4808 ,  A61K9/5026 ,  A61K9/5073 ,  A61K45/06 ,  A61K2300/00

Abstract: Oral pharmaceutical compositions and process for preparing compositions comprising at least one gastric acid suppressing agent, at least one prokinetic agent and at least one alginic acid optionally with pharmaceutically acceptable excipients are provided; such that the gastric acid suppressing agent is present in a delayed release form, prokinetic agent is present in a bimodal release form such as an immediate release form, and a delayed release form to provide a dose with a lag time form and alginic acid is present in an immediate release form. The said compositions are useful in the treatment of gastric acid related disorders such as gastro esophageal reflux disease, reflux esophagitis, peptic ulcer, gastric ulcer, heartburn, sour stomach, acid ingestion, upset stomach and/or pain associated with heartburn, sour stomach and acid ingestion, bloating, fullness, dyspepsia, nocturnal heartburn, disorders not manifested by the presence of ulcerations in the gastric mucosa, including chronic active or atrophic gastritis, and Zollinger-Ellison syndrome.

Abstract translation: 提供口服药物组合物和制备包含至少一种胃酸抑制剂，至少一种促动力剂和任选具有药学上可接受的赋形剂的至少一种藻酸的组合物的方法; 使得胃酸抑制剂以延迟释放形式存在，促动力剂以双峰释放形式存在，例如立即释放形式和延迟释放形式，以提供滞后时间形式的剂量和海藻酸 立即发布。 所述组合物可用于治疗胃酸相关疾病，例如胃食管反流病，反流性食管炎，消化性溃疡，胃溃疡，胃灼热，酸性胃，酸摄入，与胃灼热相关的胃和/或疼痛，酸性胃和 酸摄入，腹胀，饱胀，消化不良，夜间胃灼热，胃粘膜溃疡（包括慢性活动性或萎缩性胃炎）和Zollinger-Ellison综合征未出现的疾病。

公开(公告)号：WO2010029571A2

公开(公告)日：2010-03-18

申请号：PCT/IN2009/000428

申请日：2009-07-28

Applicant: PANACEA BIOTEC LIMITED ,  JAIN, Rajesh ,  SINGH, Sarabjit

Inventor： JAIN, Rajesh ,  SINGH, Sarabjit

IPC: A61K9/22 ,  A61K31/403

CPC classification number: A61K9/4808 ,  A61K9/2009 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2846 ,  A61K31/403

Abstract: The invention relates to a modified release pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipient(s) wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of ramipril administered twice daily. The invention further relates to a modified release pharmaceutical composition comprising: an immediate release component comprising ramipril or pharmaceutically acceptable salts thereof and a modified release component comprising ramipril or pharmaceutically acceptable salts thereof. The invention further relates to the process for the preparation of modified release pharmaceutical composition of ramipril.

Abstract translation: 本发明涉及包含雷米普利或其药学上可接受的盐和药学上可接受的赋形剂的调控释放药物组合物，其中药物组合物与每天两次施用的雷米普利的常规即释制剂生物等效。 本发明进一步涉及调控释放药物组合物，其包含：包含雷米普利或其药学上可接受的盐的速释组分和包含雷米普利或其药学上可接受的盐的调控释放组分。 本发明进一步涉及制备雷米普利改良释放药物组合物的方法。

公开(公告)号：WO2009110005A2

公开(公告)日：2009-09-11

申请号：PCT/IN2009/000148

申请日：2009-03-04

Applicant: PANACEA BIOTEC LIMITED ,  JAIN, Rajesh ,  SINGH, Sukhjeet

Inventor： JAIN, Rajesh ,  SINGH, Sukhjeet

IPC: A61K9/20 ,  A61K31/365

CPC classification number: A61K9/209 ,  A61K31/365

Abstract: Modified release pharmaceutical compositions comprising mycophenolate as the active agent or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof, wherein the said composition exhibits a biphasic release profile when subjected to in- vitro dissolution and/or upon administration in- vivo are provided. The composition provides a drug release in a manner such that the drug levels are maintained above the therapeutically effective concentration (EC) constantly for an extended duration of time. Further, the difference between the maximum plasma concentration of the drug (Cmax) and the minimum plasma concentration of the drug (Cmjn), and in turn the flux defined as ((Cmax - Cmjn)/Cavg) is minimal. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such compositions.

Abstract translation: 包含霉酚酸酯作为活性剂或其药学上可接受的盐，酯，多晶型物，异构体，前药，溶剂化物，水合物或其衍生物的改性释放药物组合物，其中所述组合物当经受体外溶出时显示双相释放曲线和/ 或在给予体内时提供。 组合物以使得药物水平持续高于治疗有效浓度（EC）持续延长持续时间的方式提供药物释放。 此外，药物的最大血浆浓度（Cmax）与药物的最小血浆浓度（Cmjn）之间的差异，进而定义为（（Cmax-Cmjn）/ Cavg）的通量）之间的差异最小。 本发明还提供了制备这种剂型组合物的方法以及使用这种组合物的预防和/或治疗方法。

公开(公告)号：WO2008152655A1

公开(公告)日：2008-12-18

申请号：PCT/IN2008/000369

申请日：2008-06-11

Applicant: PANACEA BIOTEC LIMITED LIMITED

Inventor： JAIN, Rajesh ,  CHAWLA, Anil, Kumar

IPC: C07K14/32 ,  C07K19/00 ,  C12N15/62 ,  C12P1/04 ,  A61K39/07

CPC classification number: C07K14/32 ,  A61K39/00 ,  A61K39/07 ,  C07K2319/55

Abstract: The present invention relates to anthrax recombinant fusion proteins, process of preparation of such proteins and compositions thereof. Particularly the recombinant fusion proteins of the present invention comprise a native Edema factor protein (EF) or mutated Edema factor protein (EFm) or truncated Edema factor protein (EFn) and a native or mutated or mature Protective Antigen (PA) optionally with a linker wherein the linker is optionally a native Lethal factor protein (LF) or mutated Lethal factor protein (LFm) or truncated Lethal factor protein (LFn). Further, provided are nucleic acids encoding the DNA construct of the present invention. The compositions of the present invention may be useful as a pre-exposure and post-exposure prophylactic and/or therapeutic vaccine against anthrax.

Abstract translation: 本发明涉及炭疽重组融合蛋白，这种蛋白质的制备方法及其组合物。 特别地，本发明的重组融合蛋白包含天然水肿因子蛋白（EF）或突变的水肿因子蛋白（EFm）或截短的水肿因子蛋白（EFn）和天然的或突变的或成熟的保护性抗原（PA），任选地具有接头 其中所述接头任选是天然致死因子蛋白（LF）或突变的致死因子蛋白（LFm）或截短的致死因子蛋白（LFn）。 此外，提供了编码本发明的DNA构建体的核酸。 本发明的组合物可用作针对炭疽的暴露前和暴露后的预防和/或治疗性疫苗。

公开(公告)号：WO2008068770A2

公开(公告)日：2008-06-12

申请号：PCT/IN2007/000274

申请日：2007-07-05

Applicant: PANACEA BIOTEC LIMITED ,  SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

Inventor： SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

IPC: A61K31/167 ,  A61K31/10 ,  A61K9/20

CPC classification number: A61K31/10 ,  A61K9/2018 ,  A61K9/2846 ,  A61K9/2886 ,  A61K31/167

Abstract: The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a higher bioavailability and improved pharmacokinetic profile as compared to a conventional bicalutamide composition.

Abstract translation: 本发明提供了一种用于在哺乳动物中产生抗雄激素作用的方法和组合物。 该方法包括向哺乳动物施用改性释放的药物组合物，其具有降低的给药频率，以改善患者的便利性和依从性。 与常规比卡鲁胺组合物相比，本发明的组合物还提供更高的生物利用度和改善的药代动力学特征。

公开(公告)号：WO2008062440A2

公开(公告)日：2008-05-29

申请号：PCT/IN2007/000392

申请日：2007-09-03

Applicant: PANACEA BIOTEC LIMITED ,  SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand ,  TANDALE, Rajendra

Inventor： SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand ,  TANDALE, Rajendra

IPC: A61K9/24

CPC classification number: A61K9/0065 ,  A61K9/2072 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/2886

Abstract: The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the system can be retained in the gastric region for a prolonged period of time. It comprises of a core, one or more layers coated over the core and a preformed hollow space. The invention also concerns with a process for preparation of the system and a method for treating/preventing diseases, by administering to a subject in need thereof, the system of the invention.

Abstract translation: 本发明涉及用于活性剂的空间和时间可编程递送的系统。 当口服给药时，可以将系统长时间保留在胃区域。 它包括一个芯，一个或多个涂层在芯上的层和预制的中空空间。 本发明还涉及用于制备该系统的方法和一种治疗/预防疾病的方法，通过向有需要的受试者施用本发明的系统。

公开(公告)号：WO2007083323A2

公开(公告)日：2007-07-26

申请号：PCT/IN2007/000022

申请日：2007-01-19

Applicant: PANACEA BIOTEC LIMITED. ,  SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

Inventor： SINGH, Amarjit ,  SINGH, Sarabjit ,  PUTHLI, Shivanand

IPC: A61K38/08 ,  A61K9/22

CPC classification number: A61K9/4808 ,  A61K9/1617 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/5084 ,  A61K38/11

Abstract: The invention describes a modified release oral dosage form of desmopressin which upon administration releases two or more amounts of desmopressin. The dosage form comprises of individual dosage units, such as an immediate release dosage unit and one or more delayed release dosage units, each comprising of a suitable amount of desmopressin, released after a predetermined time interval. The dosage form of the invention provides a release profile, adapted such that the dosage form exhibits improved efficacy for a prolonged duration of action and provides for an overall superior management of antidiuretic therapy. The invention also provides for method of manufacture of the dosage form of the invention and also method of treatment of diseases such as diabetes insipidus, nocturnal enuresis, nocturia and urinary incontinence in a mammal in need of such treatment.

Abstract translation: 本发明描述了去氨加压素的改良释放口服剂型，其在施用时释放出两种或更多量的去氨加压素。 剂型包括单个剂量单位，例如立即释放剂量单位和一个或多个缓释剂量单位，每个剂量单位包含在预定时间间隔后释放的合适量的去氨加压素。 本发明的剂型提供释放曲线，适于使得剂型在延长的作用时间内表现出改进的功效，并且提供抗利尿治疗的总体优越的管理。 本发明还提供了在需要这种治疗的哺乳动物中制备本发明的剂型的方法以及治疗诸如尿崩症，夜间遗尿，夜尿和尿失禁的疾病的方法。

公开(公告)号：WO2010038240A9

公开(公告)日：2010-04-08

申请号：PCT/IN2009/000539

申请日：2009-09-30

Applicant: PANACEA BIOTEC LIMITED ,  JAIN, Rajesh ,  SINGH, Sukhjeet

Inventor： JAIN, Rajesh ,  SINGH, Sukhjeet

IPC: A61K31/085 ,  A61K31/04 ,  A61K31/18 ,  A61K31/496 ,  A61K31/19

Abstract: The present invention relates to a composition containing nimesulide and levocetirizine useful for the treatment of allergic disorders such as rhinitis. The composition may provide different release characteristics, e.g an immediate release part and a controlled release part.

公开(公告)号：WO2009116090A3

公开(公告)日：2009-09-24

申请号：PCT/IN2009/000184

申请日：2009-03-17

Applicant: PANACEA BIOTEC LIMITED ,  JAIN, Rajesh ,  TREHAN, Sanjay ,  DAS, Jagattaran ,  KANWAR, Sandeep ,  MAGADI, Sitaram, Kumar

Inventor： JAIN, Rajesh ,  TREHAN, Sanjay ,  DAS, Jagattaran ,  KANWAR, Sandeep ,  MAGADI, Sitaram, Kumar

IPC: C07F9/6571 ,  C07F9/6509 ,  C07F9/6584 ,  C07F9/6558

Abstract: The present invention relates to novel phenyl oxazolidinone compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing conditions caused by microbial infections. The compounds of the present invention are effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant Staphylococcus spp., Streptococcus spp., Enterococcus spp., Bacterioides spp., Clostridia spp., H. influenza , Moraxella Spp., as well as acid-fast organisms such as Mycobacterium tuberculosis and the like.